Glucowatch could give diabetics updates on their health

May 23, 2000

MANY diabetics have to endure frequent, painful finger pricks to monitor their blood sugar levels. But soon just a single prick of the finger will be enough to calibrate a watch-like monitor that can measure blood sugar levels non-invasively throughout the day.

Called the GlucoWatch, the $300 device, which is close to achieving final approval by the US Food and Drug Administration, could be in production by the end of this year. Diabetes experts believe the watch will revolutionise the prospects for diabetics. Frequent blood sugar monitoring helps detect the excessively high or low blood sugar levels that lead to complications such as blindness, kidney failure and nerve damage. But many diabetics find it painful and inconvenient to check their blood sugar more than once or twice a day, so they are unaware of when they could be in danger.

The GlucoWatch, which was developed by Cygnus of Redwood City, California, sits on top of a disposable gel disc that contains the same enzyme used to measure glucose levels in home monitors. Instead of testing the blood directly, the watch draws glucose from the body into the disc using a tiny electric current flowing between two terminals beneath the watch body. As the current passes through the skin, charged molecules migrate towards the electrodes (see Diagram). Glucose molecules, although uncharged, get swept up by this ion flow and are dragged across the skin to the gel disc by the cathode.

After putting on the GlucoWatch you have to wait for three hours while a new gel pad hydrates and reaches equilibrium with the skin. After this "warm-up" period, you calibrate the device using a glucose level taken from a standard finger-prick test. After that, the watch measures glucose levels every 20 minutes for a 12-hour period. If levels go too low or too high, it sounds a warning beep.

"It's data that's never been available before," says Steven Edelman, a diabetes specialist at the School of Medicine at the University of California, San Diego. Edelman, a diabetic who has worn the GlucoWatch several times, says continuous monitoring revealed that his blood levels fell dangerously low at night while he slept. "I really learned a tremendous amount," he says.

Cygnus expects the FDA to approve the GlucoWatch as a supplement to current monitoring methods, and to advise users to perform a traditional finger-prick test before injecting insulin. Satish Garg of the University of Colorado Health Sciences Center in Denver says: "That's not real life." He worries that diabetics will base their insulin dose on the GlucoWatch alone.

Garg also fears that doctors may provide it to young children with diabetes, even though it has only been tested in adults. "This is a major concern," agrees Cygnus vice-president Neil Ackerman, who says the company wants to test the device in children as quickly as possible.
-end-
Author: Nell Boyce, Washington DC

New Scientist issue: 27th March 2000

PLEASE MENTION NEW SCIENTIST AS THE SOURCE OF THIS STORY AND, IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO: http://www.newscientist.com




New Scientist

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.